Curis (CRIS) Tops Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
Pre-Open Stock Movers 03/25: (CRIS) (AVYA) (AIMT) Higher; (PTI) (REPH) (AKAM) Lower (more...)
March 25, 2019 9:26 AM EDTToday's Pre-Open Movers
Curis, Inc. (NASDAQ: CRIS) 81% HIGHER; entered into an agreement with funds managed by Oberland Capital Management, LLC for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.
Proteostasis Therapeutics, Inc. (NASDAQ: PTI) 53.3% LOWER; announced results from Phase 1 clinical studies of its proprietary cystic fibrosis transmembrane conductance regulator (CFTR)... More
Curis (CRIS) Sells Portion of Erivedge Royalties for up to $135.7 million
March 25, 2019 8:31 AM EDTCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.
Under the terms of the agreement, Curis... More
